Delayed progression of bone metastases with bisphosphonate therapy: a randomised phase III trial with intravenous Aredia (pamidronate disodium) in breast cancer patients

Author(s):

P.F. Conte ◽

J. Latreille ◽

L. Mauriac ◽

L. Koliren ◽

F. Calabresi ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Bisphosphonate Therapy ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial ◽

Pamidronate Disodium

Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparative bone turnover marker and safety data

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)80418-0 ◽

2006 ◽

Vol 4 (2) ◽

pp. 164-165

Author(s):

J.-J. Body ◽

Lichinitser ◽

S. Tjulandin ◽

B. Bergström

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Turnover ◽

Bone Metastases ◽

Cancer Patients ◽

Bone Turnover Marker ◽

Safety Data ◽

Phase Iii ◽

Breast Cancer Patients ◽

Abstract PD07-09: Zoledronate versus ibandronate comparative evaluation (ZICE) trial - first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases.

10.1158/0008-5472.sabcs12-pd07-09 ◽

2012 ◽

Cited By ~ 2

Author(s):

PJ Barrett-Lee ◽

A Casbard ◽

J Abraham ◽

R Grieve ◽

D Wheatley ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Comparative Evaluation ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial ◽

First Results

405 POSTER Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparison of bone turnover markers

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80703-7 ◽

2005 ◽

Vol 3 (2) ◽

pp. 113 ◽

Keyword(s):

Breast Cancer ◽

Zoledronic Acid ◽

Bone Turnover ◽

Bone Metastases ◽

Cancer Patients ◽

Bone Turnover Markers ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial ◽

Turnover Markers

Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

Breast Cancer Research ◽

10.1186/bcr3179 ◽

2012 ◽

Vol 14 (3) ◽

Cited By ~ 46

Author(s):

Lynnette Fernández-Cuesta ◽

Catherine Oakman ◽

Priscila Falagan-Lotsch ◽

Ke-seay Smoth ◽

Emmanuel Quinaux ◽

...

Keyword(s):

Breast Cancer ◽

Adjuvant Therapy ◽

Cancer Patients ◽

Predictive Value ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial ◽

Node Positive ◽

Positive Breast Cancer

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

10.1158/0008-5472.sabcs13-s5-07 ◽

2013 ◽

Cited By ~ 5

Author(s):

JB Smerage ◽

WE Barlow ◽

DF Hayes ◽

EP Winer ◽

B Leyland-Jones ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Tumor Cell ◽

Cancer Patients ◽

Metastatic Breast ◽

Circulating Tumor Cell ◽

Phase Iii ◽

Breast Cancer Patients ◽

Cardiac toxicity prevention in non-metastatic breast cancer patients treated with anthracycline-based chemotherapy: A randomized, placebo controlled, phase III trial—SAFE trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps1100 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS1100-TPS1100 ◽

Author(s):

Icro Meattini ◽

Roberto Tarquini ◽

Calogero Saieva ◽

Alice Valoriani ◽

Pierluigi Bonomo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Cardiac Toxicity ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Randomized phase III trial of utidelone, a genetically engineered epothilone analog, in combination with capecitabine versus capecitabine alone for metastatic breast cancer patients with previous taxane and anthracycline treatment.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.1004 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 1004-1004

Author(s):

Binghe Xu ◽

Tao Sun ◽

Qingyuan Zhang ◽

Zhongyu Yuan ◽

Pin Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Metastatic Breast ◽

Genetically Engineered ◽

Phase Iii ◽

Breast Cancer Patients ◽

Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial

BMC Cancer ◽

10.1186/1471-2407-12-603 ◽

2012 ◽

Vol 12 (1) ◽

Cited By ~ 18

Author(s):

David Pérol ◽

Jocelyne Provençal ◽

Anne-claire Hardy-Bessard ◽

David Coeffic ◽

Jean-Phillipe Jacquin ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Early Breast Cancer ◽

Phase Iii ◽

Breast Cancer Patients ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-07-5234 ◽

2008 ◽

Vol 14 (20) ◽

pp. 6690-6696 ◽

Cited By ~ 112

Author(s):

Allan Lipton ◽

Guenther G. Steger ◽

Jazmin Figueroa ◽

Cristina Alvarado ◽

Philippe Solal-Celigny ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

Bisphosphonate Therapy ◽

Efficacy And Safety ◽

Breast Cancer Patients

A phase III trial comparing adjuvant treatment with leuprorelin acetate 3M-Depot for 24 months with CMF chemotherapy in ER/PR + node + pre-perimenopausal breast cancer patients

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.533 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 533-533 ◽

Author(s):

D. Wallwiener ◽

K. Possinger ◽

P. Schmid ◽

V. Tarutinov ◽

L. Suchina ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Adjuvant Treatment ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial ◽

Leuprorelin Acetate